Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00544466 · ClinicalTrials.gov registry record · Phase 1

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies

A Phase 1 study of Leukemia and Myelodysplastic Syndromes, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 1
Development phase
75
Enrollment target
1
Study location

NCT00544466 is a Phase 1 study of Leukemia and Myelodysplastic Syndromes that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 75 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00544466, a Phase 1 study of Leukemia and Myelodysplastic Syndromes, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and HT before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving HT together with fludarabine phosphate and melphalan before a transplant may stop this from happening. PURPOSE: This clinical trial studies helical tomotherapy (HT), fludarabine phosphate, and melphalan followed by donor stem cell transplant in treating patients with hematologic malignancies.

Conditions Studied

Leukemia Myelodysplastic Syndromes

Interventions

  • RADIATION intensity-modulated radiation therapy
  • DRUG fludarabine phosphate
  • DRUG melphalan
  • PROCEDURE allogeneic hematopoietic stem cell transplantation

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2006-07-31
Est. Completion 2026-12-02
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00544466

The ClinicalTrials.gov registry entry for NCT00544466 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (85% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 4 interventions - of which intensity-modulated radiation therapy is the first listed.

NCT00544466 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00544466 about?

NCT00544466 is a clinical study titled "Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies". RATIONALE: Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and HT before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infu...

What is the current status of trial NCT00544466?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2006-07-31. Estimated completion is 2026-12-02.

What conditions does trial NCT00544466 study?

This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes.

What interventions are being tested in trial NCT00544466?

The interventions under investigation include: intensity-modulated radiation therapy (RADIATION), fludarabine phosphate (DRUG), melphalan (DRUG), allogeneic hematopoietic stem cell transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT00544466?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00544466 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.